RxDoctor Payments Data

Laith Alkukhun, MD

Cardiovascular Disease · Portland, ORNPI 1952721060

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $10,034 of the $16,491 with a category attached, or 60.8%. Medtronic accounts for 60.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $7,280 and has fallen 84.8% since, to $1,107 in 2025. Among cardiovascular disease clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,491in general payments, 2019–2025

Across 137 payments — averaging $120.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Biotronik Inc.$2K
  • Boston Scientific$2K
  • Philips North America LLC$1K
  • Biosense Webster, Inc.$764
  • Abbott$416
  • plus $456 from 4 others

What the payments were for

  • Travel & lodging$10,03461%
  • Food & beverage$5,99936%
  • Education$4583%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,491 in reported general payments places this provider in the 90th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$299,540
Medicare patients
761
Services billed
4,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$75,290
XareltoRivaroxaban15$15,633
Flecainide Acetate54$3,665
Colchicine27$2,395
Dofetilide12$1,658
Metoprolol Succinate65$1,082
Amiodarone Hcl58$688
SotalolSotalol Hcl16$525
ClopidogrelClopidogrel Bisulfate28$183
Metoprolol Tartrate42$146
Warfarin Sodium12$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$75,29091 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →